iOmx Therapeutics AG

iOmx Therapeutics is a clinical-stage company that harnesses deep tumor and myeloid biology insights, along with its proprietary iOTargTM target screening platform, to generate novel treatments for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity, iOmx is creating potential new backbone therapies in a modality-open fashion.

The lead candidate OMX-0407, a spectrum-selective SIK kinase inhibitor, is currently being investigated in a Phase I/Ib clinical study in patients with previously treated unresectable solid tumors. First efficacy data are expected in 2025. Other pipeline programs are in earlier stages of pre-clinical development, including IOMX-0675, a cross-specific antibody, simultaneously targeting the immunosuppressive receptors LILRB1 & LILRB2. IOMX-0675 will enter clinical development in early 2025.

Founded in 2016 and based in Martinsried / Munich, the company traces its scientific roots to the German Cancer Research Center. iOmx has raised over €100m and is backed by international venture capital investors, including Athos, Sofinnova Partners, Wellington Partners, MIG Capital and M Ventures.